Several Actionable Targets Identified in Testicular Cancer

Video

This video highlights recent research in cisplatin-resistant testicular cancer, including a study on whole exome sequencing that revealed several actionable targets.

In this video, Aditya Bagrodia, MD, of the University of Texas Southwestern Medical Center, discusses recent research in germ cell tumors.

A recent study that used whole exome sequencing in platinum-resistant disease revealed that many of these patients have actionable targets.

Bagrodia, who gave a presentation on this topic at the 2017 Genitourinary Cancers Symposium in Orlando, Florida, also looks ahead toward trials examining the potential of different immunotherapies in this setting.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.

Loncastuximab Tesirine Combo Is Effective, Safe in R/R Follicular Lymphoma

April 25th 2024
Article

Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

Cilta-cel Shows High Responses for Lenalidomide-Refractory Myeloma in First Relapse

April 25th 2024
Article

The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.

Eftilagimod Alpha/Pembrolizumab Elicits Encouraging Responses in HNSCC

April 25th 2024
Article

The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

European Commission Approves Enzalutamide in nmHSPC Subset

April 25th 2024
Article

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.